Brought to you by 
Series B generates €27.5mm for arGEN-X BV; adds €5mm
06 Nov 2013
Executive Summary
Dutch antibody therapeutics developer arGEN-X BV has raised €27.5mm ($37mm) through its oversubscribed Series B financing led by new investors OrbiMed Advisors (added a board member) and Seventure Partners, which were joined by returning shareholders Forbion Capital Partners, Credit Agricole Private Equity, Life Sciences Partners, BioGeneration Ventures, Erasmus Biomedical Fund, Thuja Capital, and Flemish research institute VIB. Funds will support ongoing development of antibodies based on its SIMPLE Antibody platform. The company raised €12.5mm via its Series A round in 2009.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B generates €27.5mm for arGEN-X BV; adds €5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice